• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Tuberculosis/ Other Mycobacterium  • Treatment Adherence  • Drug Therapy  • Adherence  • Adverse Effects  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Retrospective Study

Kathleen R. Page, MD; Frangiscos Sifakis, PhD; Ruben Montes de Oca, PhD; Wendy A. Cronin, PhD; Meg C. Doherty, MD, PhD; Lynn Federline, RN; Sarah Bur, RN; Thomas Walsh, MD; Walter Karney, MD; James Milman, MD; Nancy Baruch, RN; Akintoye Adelakun, MD; Susan E. Dorman, MD

Arch Intern Med. 2006;166:1863-1870.

Background  Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen. In this study, we compared treatment completion and clinically recognized adverse drug reactions in patients prescribed 9 months of isoniazid therapy or 4 months of rifampin therapy for LTBI.

Methods  Retrospective chart review of patients who received LTBI treatment at a public health clinic.

Results  A total of 770 patients were prescribed 9 months of isoniazid therapy, and 1379 patients were prescribed 4 months of rifampin therapy. The percentages of patients who completed 80% or more of their prescribed treatment were 52.6% and 71.6% in the isoniazid and rifampin groups, respectively (P<.001). In multivariate logistic regression analysis, treatment regimen was independently associated with treatment completion (adjusted odds ratio for treatment completion, 2.88 for rifampin group vs isoniazid group; 95% confidence interval, 2.27-3.66). Clinically recognized adverse reactions resulting in permanent treatment discontinuation occurred in 4.6% and 1.9% of patients in the isoniazid and rifampin groups, respectively (P<.001). Clinically recognized hepatotoxicity was more common in the isoniazid group (1.8%) than in the rifampin group (0.08%, P<.001).

Conclusions  Compared with a 9-month isoniazid regimen, a 4-month rifampin regimen was associated with a higher percentage of patients completing treatment and a lower percentage of patients with clinically recognized adverse reactions. Additional studies are warranted to determine efficacy and effectiveness of rifampin therapy for LTBI.

Author Affiliations: Department of Medicine, Johns Hopkins University School of Medicine (Drs Page, Doherty, and Dorman), Departments of Epidemiology (Drs Sifakis and Montes de Oca) and International Health (Dr Dorman), Johns Hopkins Bloomberg School of Public Health, and Maryland State Department of Health and Mental Hygiene (Dr Cronin and Mss Bur and Baruch), Baltimore, Md; and Prince George's County Tuberculosis Control Program, Cheverly, Md (Ms Federline and Drs Walsh, Karney, Milman, and Adelakun).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Influence of replacing tuberculin skin test with ex vivo interferon {gamma} release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy
Mariette et al.
Ann Rheum Dis 2012;0:annrheumdis-2011-200408v1-annrheumdis-2011-200408.
ABSTRACT | FULL TEXT  

Hepatic safety of antibiotics used in primary care
Andrade and Tulkens
J Antimicrob Chemother 2011;66:1431-1446.
ABSTRACT | FULL TEXT  

Treatment of latent infection with Mycobacterium tuberculosis: update 2010
Leung et al.
Eur Respir J 2011;37:690-711.
ABSTRACT | FULL TEXT  

Tuberculosis contact investigation in low prevalence countries: a European consensus
Erkens et al.
Eur Respir J 2010;36:925-949.
ABSTRACT | FULL TEXT  

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB
Aspler et al.
Thorax 2010;65:582-587.
ABSTRACT | FULL TEXT  

Latent TB Infection Treatment Acceptance and Completion in the United States and Canada
Horsburgh et al.
Chest 2010;137:401-409.
ABSTRACT | FULL TEXT  

4 Months of Rifampin Compared with 9 Months of Isoniazid for the Management of Latent Tuberculosis Infection: A Meta-analysis and Cost-Effectiveness Study That Focuses on Compliance and Liver Toxicity
Ziakas and Mylonakis
Clinical Infectious Diseases 2009;49:1883-1889.
ABSTRACT | FULL TEXT  

Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection
Zhang et al.
Am. J. Respir. Crit. Care Med. 2009;180:1151-1157.
ABSTRACT | FULL TEXT  

A Retrospective Evaluation of Completion Rates, Total Cost, and Adverse Effects for Treatment of Latent Tuberculosis Infection in a Public Health Clinic in Central Massachusetts
Young et al.
Clinical Infectious Diseases 2009;49:424-427.
ABSTRACT | FULL TEXT  

Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection
Holland et al.
Am. J. Respir. Crit. Care Med. 2009;179:1055-1060.
ABSTRACT | FULL TEXT  

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Menzies et al.
ANN INTERN MED 2008;149:689-697.
ABSTRACT | FULL TEXT  

Needed: New and Better Tools to Combat Latent Tuberculosis Infection
Blumberg
ANN INTERN MED 2008;149:761-763.
FULL TEXT  

Reply to Ijaz et al
Cook
Clinical Infectious Diseases 2007;44:465-465.
FULL TEXT  

Treatment of latent tuberculosis with rifampicin is associated with higher completion rates
Nadig
Thorax 2007;62:167-167.
FULL TEXT